Attention deficit hyperactivity disorder

EARTHDAY.ORG RELEASES REPORT BABIES VS. PLASTICS

Retrieved on: 
Thursday, November 16, 2023

With over 100+ studies, reports and articles reviewed – BABIES VS. PLASTICS makes for shocking reading:

Key Points: 
  • With over 100+ studies, reports and articles reviewed – BABIES VS. PLASTICS makes for shocking reading:
    Research suggests the health implications presented by microplastics and their additive chemicals extend to children both before and after birth.
  • Some studies report finding links between microplastics and attention deficit hyperactivity disorder (ADHD).
  • Evidence (from a pilot study) suggests babies, more than any other demographic group, might be more susceptible to ingesting microplastics.
  • Babies taste test their world, which often mean chewing on plastics.

EARTHDAY.ORG RELEASES REPORT BABIES VS. PLASTICS

Retrieved on: 
Thursday, November 16, 2023

With over 100+ studies, reports and articles reviewed – BABIES VS. PLASTICS makes for shocking reading:

Key Points: 
  • With over 100+ studies, reports and articles reviewed – BABIES VS. PLASTICS makes for shocking reading:
    Research suggests the health implications presented by microplastics and their additive chemicals extend to children both before and after birth.
  • Some studies report finding links between microplastics and attention deficit hyperactivity disorder (ADHD).
  • Evidence (from a pilot study) suggests babies, more than any other demographic group, might be more susceptible to ingesting microplastics.
  • Babies taste test their world, which often mean chewing on plastics.

ADHD drug shortages are affecting patients in the UK – here's why they're happening

Retrieved on: 
Tuesday, November 7, 2023

Millions of people in the UK who take drugs for attention deficit hyperactivity disorder (ADHD) are facing difficulties getting their prescriptions filled due to shortages.

Key Points: 
  • Millions of people in the UK who take drugs for attention deficit hyperactivity disorder (ADHD) are facing difficulties getting their prescriptions filled due to shortages.
  • These shortages are currently affecting four of the five types of medicine licensed in the UK to treat ADHD.

What’s causing these shortages?

  • Not only that, but a growing number of adults are now being diagnosed with ADHD – meaning that even more people are seeking access to ADHD drugs.
  • For example, between April and June 2023 about 202,000 new people in England received a prescription for these drugs.
  • Multiple factors have been linked to this shortage – including a manufacturing delays, increased demand, restrictions on what drugs pharmacists can supply and quota issues.
  • In the US, the quotas may be too low, manufacturing may not be optimised, or the right people may not be receiving the products, causing shortages.
  • There are now reports that people are also having difficulty filling other ADHD medications, such as Concerta and Focalin.

Managing shortages

  • They can help them concentrate better, be less impulsive, feel calmer and learn and practise new skills.
  • Some patients report rationing their prescriptions to make them last longer or have taken to stockpiling them.
  • Patients who have been affected will have been notified by their normal pharmacy of any supply issues.
  • Changing medications or prescribed dosages can sometimes be a strategy to manage shortages so that patients can continue treatment.
  • It’s also unclear if the shortages will be resolved by the end of 2023 as predicted.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023

“We continue to successfully execute on our 2023 key initiatives as demonstrated by our third quarter 2023 results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our 2023 key initiatives as demonstrated by our third quarter 2023 results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • The Company is on track to commence its initial Phase 3 pivotal PK study for Anaphylm in the fourth quarter 2023.
  • Total reported revenues were $13.0 million in the third quarter 2023, compared to $11.5 million in the third quarter 2022.
  • Aquestive is updating its full-year 2023 financial guidance based on third quarter 2023 results and updated outlook for the remainder of 2023.

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Retrieved on: 
Monday, November 6, 2023

SALT LAKE CITY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2023. The Company also provided an update on its business performance and 2023 financial guidance.

Key Points: 
  • GAAP gross margins of 70.0% in the third quarter of 2023; adjusted gross margins for the third quarter of 2023 was 70.4%, an increase of 140.0 basis points from the second quarter of 2023.
  • The Myriad Genetics Oncology business provides hereditary cancer testing, including the MyRisk® hereditary cancer test for patients who have cancer.
  • Prolaris continued to see healthy demand as third quarter testing revenue and volumes grew 18% and 9% year-over-year, respectively.
  • 16_suppl (June 01, 2023)5030
    Myriad Genetics updates its 2023 revenue and non-GAAP financial guidance, as stated in the table below.

Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder

Retrieved on: 
Monday, October 30, 2023

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ DYANAVEL® XR (amphetamine) extended-release tablets.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ DYANAVEL® XR (amphetamine) extended-release tablets.
  • The program is available across the United States, enabling nationwide access to DYANAVEL XR extended-release tablets.
  • Patients and physicians wishing to access the DYANAVEL Delivered program can learn more at www.dyanavel.com/delivered .
  • The DYANAVEL Delivered program is designed to help eliminate bottlenecks by delivering DYANAVEL XR extended-release tablets directly to patients and caregivers.

PHIT America Welcomes Two New Members to Its National Board

Retrieved on: 
Thursday, November 2, 2023

"The moment I met Aubrey and Eric I knew they would become important additions to our Board," said Baugh. "These gentlemen have the knowledge and networks we need to impact millions of kids. Their passion for kids' fitness and health, and the fact that they are leaders in key areas impacted by the 'Inactivity Pandemic' -- military and sports – make them both ideal board members."

Key Points: 
  • WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- PHIT America president Jim Baugh today announced the addition of two new members to its board of directors.
  • The latest business leaders added to PHIT's board include retired Marine Gunnery Sergeant Aubrey McDade and retired NFL player Eric Swann.
  • "The moment I met Aubrey and Eric I knew they would become important additions to our Board," said Baugh.
  • PHIT America is led by Sports Industry and Tennis Industry Hall of Fame Inductee, and former President of Wilson Sporting Goods, Jim Baugh .

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Retrieved on: 
Thursday, October 26, 2023

The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.

Key Points: 
  • The potential license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
  • The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation.
  • ABVC and AiBtl are determined to collaborate on the global development of the Licensed Products.
  • They are also working to strengthen their new drug development and business collaboration, including technology, interoperability, and standards development.

Kye Pharmaceuticals partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada

Retrieved on: 
Thursday, October 26, 2023

MISSISSAUGA, ON, Oct. 26, 2023 /CNW/ - Kye Pharmaceuticals Inc. ("Kye"), a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA ("Hyloris"), a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine.

Key Points: 
  • MISSISSAUGA, ON, Oct. 26, 2023 /CNW/ - Kye Pharmaceuticals Inc. ("Kye"), a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA ("Hyloris"), a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine.
  • Through this partnership, Kye becomes the exclusive Canadian rights holder for the Atomoxetine Oral Solution developed by Hyloris.
  • Under the terms of the agreement, Kye is responsible for the registration and commercialization of this product in Canada.
  • Atomoxetine Oral Solution may be indicated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and over, adolescents, and adults.

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada

Retrieved on: 
Tuesday, October 24, 2023

In 2022, the Canadian market amounted to 17 million capsules (CAGR of 7,4% in the period 2020-2022)4 of atomoxetine.

Key Points: 
  • In 2022, the Canadian market amounted to 17 million capsules (CAGR of 7,4% in the period 2020-2022)4 of atomoxetine.
  • Atomoxetine is currently not available as an oral liquid formulation in Canada.
  • Considering the added value, significant market share penetration was often observed in countries when an oral liquid became available in this drug category5.
  • The territorial expansion for atomoxetine oral liquid should not result in additional product-related investments for Hyloris.